Using renal resistive index to predict acute kidney injury progression in ICU patients
The Role of Renal Resistive Index (RI) in Predicting Acute Kidney Injury Progression and Need for Renal Replacement Therapy in Patients Followed in the Intensive Care Clinic
This study is testing if a special ultrasound measurement can help doctors predict how acute kidney injury will progress in ICU patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Gulhane Training and Research Hospital Government |
| Locations | 1 site (Ankara, Türkiye) |
| Trial ID | NCT06995222 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of renal resistive index (RRI) in predicting the progression of acute kidney injury (AKI) in patients admitted to the intensive care unit (ICU). It aims to evaluate the effectiveness of RRI, measured through Doppler ultrasound, as a biomarker for early detection of AKI and its potential outcomes. The study will include patients over 18 years old who meet specific KDIGO criteria for AKI within the first 24 hours of ICU admission. By analyzing RRI data, the researchers hope to improve understanding of renal perfusion and its implications for patient management in critical care settings.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been diagnosed with stage 1 or stage 2 acute kidney injury within the first 24 hours of ICU admission.
Not a fit: Patients with chronic kidney disease, those who are pregnant, or individuals with postrenal acute kidney injury will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better management of acute kidney injury in critically ill patients.
How similar studies have performed: Previous studies have shown that renal resistive index is a promising marker for early detection of renal injury, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Being over 18 years of age 2. Having KDIGO stage 1 or stage 2 acute kidney injury within the first 24 hours of admission Exclusion Criteria: * 1\. Patients who did not provide a consent form for participation in the study 2. Patients under 18 years of age 3. Pregnant women 4. Patients with postrenal acute kidney injury 5. Patients 24 hours after the diagnosis of acute kidney injury 6. Patients with acute kidney injury in the recovery period 7. Patients who were evaluated as KDIGO ABH stage 3 during hospitalization 8. Patients with a known history of renal artery stenosis 9. Patients with a diagnosis of cardiac arrhythmia 10. Patients with a diagnosis of chronic kidney disease and a glomerular filtration rate below 30 ml/min/1.73m2 11. Patients with intra-abdominal pressure above 20 mmHg 12. Patients with a hospitalization period of less than 24 hours
Where this trial is running
Ankara, Türkiye
- Gulhane Education and Research Hospital Ankara Türkiye — Ankara, Türkiye, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Mete E specialist
- Email: meteerdemir@hotmail.com
- Phone: +905066321175
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.